Intervacc develops veterinary vaccines based on fusions of recombinant proteins. Our first inhouse developed vaccine Strangvac® is now in the regulatory phase and we are planning for a positive opinion from European Medicines Agency, EMA during the second quarter 2021.
In addition to Strangvac®, we have an exciting development portfolio of veterinary vaccine projects that are in a pre-clinical phase.
The Intervacc group also include Nordvacc, who markets and distribute products within the Animal Health segment in the Nordics. Mybac-Vettech a accredited veterinary laboratory in bacteriology and mycology is another important operation included in the group and alltogether we have a clear focus on Animal Health.
Our investors section includes information regarding our market, major shareholders, corporate governance and a financial calendar. External analyzes of the company are conducted by ABG Sundal Collier, among others, and these are presented at Introduce Equity Research.
We look forward to you taking part of the information and hope to welcome you as a shareholder and to participate in an exciting development towards new, safe and effective vaccines within Animal Health.
ABGSC Investor Day
Intervacc participated in ABGSC Investor Day on September 7, 2020 in Stockholm. CEO Andreas Andersson presented the company and a resume of the first half year. With a strong cash position we now have the opportunity to act long-term and aggressively in the global launch of Strangvac®, our vaccine against the horse disease strangles.
Here you can see the recorded presentation which is about 26 minutes including the following Q&A.
